NASD · Healthcare · Biotechnology · Germany
Immatics N.V is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.
Intrinsic value, DCF valuation, financial health and value investing analysis for the Immatics N.V stock.
Overvalued: intrinsic value $3.34 per share, market price $7.20, margin of safety -115.3% (as of 2026-10-30).
Its liquidation floor, current assets minus every liability, values the shares at $3.34; the price of $7.20 is 115% above that value.
1 more funds hold it; the full list is part of the paid plan.
55 more in this industry show a wider margin of safety.
IMTX is overvalued (as of the 2026-10-30 close). Its liquidation floor, current assets minus every liability, values the shares at $3.34; the price of $7.20 is 115% above that value.
$3.34 per share (as of the 2026-10-30 close), against a market price of $7.20. That is a margin of safety of -115.3%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.